%0 Journal Article %T Ellagic Acid Holds Promise Against Hepatocellular Carcinoma in an Experimental Model: Mechanisms of Action %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Zaazaa, Asmaa M %A Lokman, Maha S %A Shalby, Aziza B %A Ahmed, Hanaa H %A El-Toumy, Sayed A %D 2018 %\ 02/01/2018 %V 19 %N 2 %P 387-393 %! Ellagic Acid Holds Promise Against Hepatocellular Carcinoma in an Experimental Model: Mechanisms of Action %K Hepatocellular carcinoma %K N-nitrosodiethylamine %K ellagic acid %K doxorubicin %K Rats %R 10.22034/APJCP.2018.19.2.387 %X This research work was initiated to explore the efficacy of ellagic acid in mitigation of hepatocarcinogenesis inrats. Rats were distributed into 4 groups; negative control, hepatocellular carcinoma (HCC), doxorubicin and ellagicacid. Serum alpha-fetoprotein (AFP), glypican-3 (GPC-3), signal transducer and activator of transcription 3 (STAT3)and suppressors of cytokine signaling 3 (SOCS3) levels were assayed by ELISA. Immunohistochemical examinationof hepatic VEGF expression was also conducted, along with histological procedures for examination of liver tissuesections. Significant elevation in serum AFP, GPC-3 and STAT3 levels with a significant drop in SOCS3 were observedin the HCC group. In contrast, the treated groups showed significant decline in serum AFP, GPC-3 and STAT3 levelsand significant increase in SOCS3. Additionally, the HCC group declared mild positive immunoreaction for VEGF inhepatocytes while treatment with doxorubicin or ellagic acid was associated with a negative immunoreaction for VEGF.These results were supported by histological examination of liver tissue. The obtained findings suggested that ellagicacid may have beneficial chemopreventive role against hepatocarcinogenesis through its apoptotic, antiangiogenic andantiproliferative activities. %U https://journal.waocp.org/article_57578_9098b8b1af0bb1c1041f5ba0bb36e2c9.pdf